A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Multiple Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0822 in Healthy Male and Postmenopausal Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Odanacatib (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co
- 01 Aug 2009 Results published in Clinical Pharmacology and Therapeutics.
- 22 Oct 2008 New trial record.